Abstract
Data management in clinical trials is an activity performed with high ambitions but under undefined regulatory requirements as to the quality of the data presented in the trial reports. The term quality is not defined but its use implies a degree of absence from measurement errors. The term error is not defined but its use indicates an unexplained difference between the original recording of measurement and data presented in the final report. From a review of modern quality management methods in comparison to standard procedures in clinical data management it is apparent that there are striking differences in many aspects on how to assure high quality. On basis of this review it is suggested that the major obstacle for obtaining high quality is the traditional dependence on repeated reviews of inconsistent data late after the original measurements have been made. More systematic use of experience and resources, in particular for training investigators, should be made to prevent errors.
Similar content being viewed by others
References
Deming WE. Out of the Crisis. Cambridge, MA: Massachusetts Institute of Technology, Center for Advanced Engineering Study; 1986.
Knatterud GL, Rockhold FW, George SL, Barton FB, Davis CE, Fairweather WR, Honohan T, Mowery R, O’Neill R. Guidelines for quality assurance in multicenter trials: A position paper. Control Clin Trials. 1998;19:477–493.
McEntegart DJ, Jadhav PS, Brown T, Channon EJ. Checks of case record forms versus the database for efficacy variables when validation programs exist. Drug Inf J. 1999;33:101–107.
World Medical Association. Declaration of Helsinki, recommendations guiding physicians in biomedical research involving human subjects. Geneva, Switzerland: World Medical Association; 1996.
Day S, Fayers P, Harvey D. Double data entry: what value, what price? Control Clin Trials. 1998;19:15–24.
Shewhart WA. Economic Control of Quality of Manufactured Product. New York, NY: Van Nostrand; 1931.
Van Nuland YV. Do you have doubts about the measurement results, too? Quality Engineering. 1993;6(1):99–113.
Fenguy Z, Bergman B. The Method and Software for Measurement System Analysis and Control. Linköping, Sweden: Conference Proceedings, First International Symposium on Industrial Statistics; 1999.
Curran CF. Preparing a clinical site for a clinical investigator inspection by the FDA. Drug Inf J. 1999;33:253–259.
Juran JM. Juran on Quality by Design. New York, NY: McGraw-Hill; 1992.
US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production. Rockville, MD: US Food and Drug Administration; 1998.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lörstad, M.H. From “Too Much, Too Late” to “Right First Time”: Quality Guru Deming’s Advice for Clinical Trials. Ther Innov Regul Sci 34, 1319–1328 (2000). https://doi.org/10.1177/009286150003400439
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150003400439